Key Takeaway: Precision BioSciences, Inc. has announced the date for its third quarter financial results, which will be published on November 4, 2024. The company focuses on developing in vivo gene editing therapies using its proprietary ARCUS platform. This announcement signals ongoing progress in their clinical stage initiatives.
Price reaction · baseline $6.5 (2024-11-21 close) · hit pre-market · 3 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
+11.7%
day 1
+11.4%
day 3
+9.4%
Market Sentiment Analysis
POSITIVE FACTORS
Precision BioSciences is advancing its gene editing therapies.
The company is utilizing its proprietary ARCUS platform.
Upcoming financial results may indicate positive growth.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
DURHAM, N.C. –(BUSINESS WIRE)–Oct. 29, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will publish financial
Frequently Asked Questions
When will Precision BioSciences report its Q3 results?
Precision BioSciences will report its third quarter results on November 4, 2024.
What platform does Precision BioSciences use?
The company utilizes its proprietary ARCUS platform for gene editing therapies.
What is the focus of Precision BioSciences?
Precision BioSciences focuses on developing in vivo gene editing therapies.